HOME >> BIOLOGY >> NEWS
Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertex's Investigational IMPDH Inhibitor VX-497

The investigational drug VX-497 may have potent, broad-spectrum antiviral activity, according to laboratory results presented by scientists from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) at the 12th International Conference on Antiviral Research held this week in Jerusalem, Israel. VX-497's activity against viruses in cell culture was compared to that of the antiviral compound ribavirin, both alone and in combination with interferonalpha. Vertex is evaluating VX-497 in Phase II clinical trials for HCV infection and as an immunosuppressant for psoriasis.

VX-497 is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), a human enzyme that is essential for the de novo production of guanosine nucleotides (for example, GTP)-one of the building blocks of RNA and DNA. Inhibition of IMPDH may be an effective strategy for blocking the rapid proliferation (growth) of certain cell types which uniquely depend upon this de novo pathway--such as B and T lymphocytes--as well as blocking viral replication, which is often more dependent on the de novo pathway than on the alternative "salvage" pathway of nucleotide biosynthesis used by most human cells.

In one study comparing the activity of VX-497 versus ribavirin against selected DNA and RNA viruses in vitro, VX-497 was found to be 15-to 186-fold more potent than ribavirin against hepatitis B virus, human cytomegalovirus, respiratory syncytial virus, herpes simplex virus type 1, parainfluenza-3 virus, and Venezuelan equine encephalitis virus. Preliminary data suggests VX-497 may be more potent than ribavirin against bovine viral diarrhea virus and as potent as ribavirin against dengue virus.

In another study, using cells infected with encephalomyocarditis virus (EMCV), VX-497 was shown to have 15-to 40-fold more potent antiviral activity in combination with interferon-alpha, when compared to a combination of ribavirin plus interferon-alpha. Ribavirin is marketed in the
'"/>

Contact: Michele Karpf
karpf@vpharm.com
617-577-6259
Vertex Pharmaceuticals
25-Mar-1999


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Research suggests new avenue for stopping, preventing colon cancer
10. Researchers develop fast track way to discover how cells are regulated
11. Research on carbohydrate metabolism receives historical recognition

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... ... September 12, 2018 , ... JoVE, the leading producer and ... the professional development of academic librarians by sponsoring four award-winners to attend the ... to submit successful strategies to increase collaboration among librarians and STEM faculty and ...
(Date:9/7/2018)... (PRWEB) , ... September 06, 2018 , ... ... Amedica Corporation (NASDAQ: AMDA) to purchase its commercial spine business, which includes its ... directly related to the spine that result from it. The deal will make ...
(Date:8/31/2018)... ... August 30, 2018 , ... In ... a component of drug discovery programs. Longer-target engagement can result in improved efficacy ... throughput, require expensive instrumentation, or require the alteration of the molecules involved. The ...
Breaking Biology News(10 mins):
(Date:9/22/2018)... ... September 20, 2018 , ... ... announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights ... comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space. ...
(Date:9/15/2018)... ... 14, 2018 , ... Next-generation genomic sequencing is transforming what is known about ... In the past, the sheer size of genomics data has made sharing across the ... ecosystem developed to advance cures by reducing the technological barriers to data sharing and ...
(Date:9/12/2018)... ... 2018 , ... Franz Inc. , an early innovator in Artificial Intelligence ... Graphs, and Semantic Web Company , developers of the PoolParty Semantic Suite ... the Noam Chomsky Knowledge Graph. This project is the first aimed at ...
(Date:9/12/2018)... ... September 12, 2018 , ... NDA Partners Chairman Carl Peck, ... Director of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined the ... and Quality Systems at WellDoc, Inc., she conducted quality control and supplier audits, ...
Breaking Biology Technology:
Cached News: